Skip to main content
a16z Podcast

Mark Zuckerberg & Priscilla Chan: How AI Will Help Cure Disease

45 min episode · 2 min read
·

Episode

45 min

Read time

2 min

Topics

Productivity, Relationships, Artificial Intelligence

AI-Generated Summary

Key Takeaways

  • Tool-first science strategy: Rather than funding individual disease therapies, CZI invests $100M–$1B over 10–15 year horizons to build shared infrastructure — datasets, imaging systems, AI models — that the entire scientific community can access freely. This approach mirrors how the microscope and telescope unlocked prior scientific revolutions by enabling observation of previously invisible phenomena.
  • CellxGene network effect: CZI built CellxGene originally as a single-cell data annotation tool to solve a workflow bottleneck. Standardized formatting caused organic adoption across the broader research community, resulting in a cell atlas where 75% of contributed data came from external researchers — not CZI-funded labs — demonstrating how open tooling creates compounding scientific returns.
  • Virtual cell model hierarchy: CZI is building virtual cell models in layers — proteins first (via Evolutionary Scale partnership), then cellular behavior, then systems like a virtual immune system. Models like Variantformer predict CRISPR edit outcomes; a diffusion model generates synthetic rare cell configurations. This hierarchy lets researchers test hypotheses computationally before expensive wet lab experiments.
  • Biohub geographic specialization: Three Biohubs address distinct biological challenges: San Francisco focuses on deep imaging and transcriptomics, Chicago studies cell communication within tissues and inflammation, New York works on cell engineering for in-body signal detection. Each hub partners with local universities — UCSF, Stanford, Berkeley, University of Chicago — to enable cross-disciplinary collaboration between biologists and engineers.
  • Compute as the new lab space: CZI operates a 1,000-GPU compute cluster with plans to scale to 10,000 GPUs, which it opens to external scientists via a competitive application process. Individual academic labs typically operate with tens of GPUs, making this cluster access a meaningful capability multiplier for researchers pursuing questions that require large-scale computational resources unavailable through standard grant funding.

What It Covers

Mark Zuckerberg and Priscilla Chan outline how the Chan Zuckerberg Initiative's Biohub network is combining frontier AI with frontier biology to build shared scientific tools — including cell atlases, virtual cell models, and protein models — targeting disease elimination by end of century, now potentially sooner.

Key Questions Answered

  • Tool-first science strategy: Rather than funding individual disease therapies, CZI invests $100M–$1B over 10–15 year horizons to build shared infrastructure — datasets, imaging systems, AI models — that the entire scientific community can access freely. This approach mirrors how the microscope and telescope unlocked prior scientific revolutions by enabling observation of previously invisible phenomena.
  • CellxGene network effect: CZI built CellxGene originally as a single-cell data annotation tool to solve a workflow bottleneck. Standardized formatting caused organic adoption across the broader research community, resulting in a cell atlas where 75% of contributed data came from external researchers — not CZI-funded labs — demonstrating how open tooling creates compounding scientific returns.
  • Virtual cell model hierarchy: CZI is building virtual cell models in layers — proteins first (via Evolutionary Scale partnership), then cellular behavior, then systems like a virtual immune system. Models like Variantformer predict CRISPR edit outcomes; a diffusion model generates synthetic rare cell configurations. This hierarchy lets researchers test hypotheses computationally before expensive wet lab experiments.
  • Biohub geographic specialization: Three Biohubs address distinct biological challenges: San Francisco focuses on deep imaging and transcriptomics, Chicago studies cell communication within tissues and inflammation, New York works on cell engineering for in-body signal detection. Each hub partners with local universities — UCSF, Stanford, Berkeley, University of Chicago — to enable cross-disciplinary collaboration between biologists and engineers.
  • Compute as the new lab space: CZI operates a 1,000-GPU compute cluster with plans to scale to 10,000 GPUs, which it opens to external scientists via a competitive application process. Individual academic labs typically operate with tens of GPUs, making this cluster access a meaningful capability multiplier for researchers pursuing questions that require large-scale computational resources unavailable through standard grant funding.

Notable Moment

When CZI announced its goal to help cure all disease by century's end, biologists called it unreachable while AI researchers called it inevitable and boring. That gap — between biological skepticism and AI overconfidence — is precisely the space CZI positions itself to bridge through combined frontier work.

Know someone who'd find this useful?

Episode Transcript

This is a a a space that I mean, that there's just gonna be a huge amount of leverage with AI. It still seems like there could be a lot more effort in this space around building tools, and it's kind of this crazy thing that we're, you know, here in, you know, 2025, and there's not the kind of periodic table of elements equivalent for biology. We think that this is, like, probably one of the most important sets of tools that you need to build. When we first set out that the goal to cure and prevent disease by the end of the century, people, like, honestly, most scientists couldn't look at us with a straight face. And They're like, you're crazy. Yes. And it was true because if you just decide to spend the money funding the next best grant for every single lab in the country, like, you there's no pathway to that being true. The biology folks, I think, looked at it as if it were crazy ambitious. And then the AI folks are like, well, that's kinda boring. That's just automatically gonna happen. Yeah. Yeah. I know. That's like, okay. There's something in between there that needs to be bridged. For our summer replay series, we're bringing back one of our favorite conversations from the past year. As AI continues to reshape nearly every industry, one of its most important applications may be in science itself. In this conversation, Mark Zuckerberg and doctor Priscilla Chan discuss the Chan Zuckerberg's initiative's long term effort to accelerate scientific discovery by building new tools for biology. Rather than focusing on individual therapies, they're investing in the infrastructure, datasets, and AI systems they believe researchers will need to make faster progress against disease. We explore Cell Atlas, virtual cell models, Biohub, and the idea that the future of medicine may depend as much on better tools as on better treatments. Mark Priscilla, welcome to the ASX Z podcast. Thanks for having us. Yeah. Great to be here. Excited. Alright. Excited to have you. You're doing exciting stuff. Yeah. To that end, almost a decade ago, you guys started the Chan Zuckerberg Initiative with the mission and intent to cure, prevent, manage all disease by the end of this century. There's a lot of missions that you guys could have poured your time and resources into. Take us behind the conversations of why you guys picked this one. Maybe Priscilla, why don't we start with you and your side of the story? It always surprises people when I talk about how we work in basic science research. I trained as a pediatrician, and people always think, oh, it must be about medicine. And for me, I went into medicine because I wanted to improve people's lives. I wanted to make a difference. I wanted to be able to help others. And I think training as a pediatrician at UCSF, I met a lot of patients and, frankly, like, little …

Get the full transcript (8,626 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all a16z Podcast transcripts →

You just read a 3-minute summary of a 42-minute episode.

Get a16z Podcast summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

Books, tools, and gear mentioned in this episode

SignalCast may earn commission on purchases via these links.

Tools

  • by Chan Zuckerberg Initiative

    CZI built CellxGene originally as a single-cell data annotation tool to solve a workflow bottleneck. Standardized formatting caused organic adoption across the broader research community, resulting in a cell atlas where 75% of contributed data came from external researchers.
  • Models like Variantformer predict CRISPR edit outcomes; a diffusion model generates synthetic rare cell configurations.

company

  • CZI is building virtual cell models in layers — proteins first (via Evolutionary Scale partnership), then cellular behavior, then systems like a virtual immune system.

More from a16z Podcast

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's AI & Machine Learning Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into a16z Podcast.

Every Monday, we deliver AI summaries of the latest episodes from a16z Podcast and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime